mapk

youtube

The cardinal lesion of diabetic nephropathy resides in renal glomeruli and is called diabetic glomerulosclerosis, hyperglycemia is responsible for the development and progression of diabetic nephropathy through metabolic derangements, including increased oxidative stress, renal polyol formation, activation of protein kinase C (PKC) mitogen activated protein kinases (MAPKs), and accumulation of advanced glycation end products, as well as such hemodynamic factors as systemic hypertension and increased intraglomerular pressure

Mu'allimin Mengguncang MAPK FAIR 2015

Event lomba MAPK Fair dari MAN 1 Surakarta menyediakan berbagai macam lomba keagaman untuk siswa SMP/MTS Tsanawiyah sederajat se-Jawa pada tanggal 1 Maret 2015, seperti:

  1. Pidato Bahasa Inggris
  2. Pidato Bahasa Indonesia
  3. Pidato Bahasa Arab
  4. Story Telling
  5. Musabaqah Tilawatil Qur'an
  6. Musabaqah Hifdzil Qur'an

Dan kali ini, Madrasah Mu'allimin Muhammadiyah Yogyakarta mengirimkan 10 delegasinya, yakni:

  1. Arsyad Amanat Robbani ( 7F ) Story Telling
  2. Andi Aqillah Fadia Haswat ( 9F ) Story Telling
  3. Arif Rachman Mustafa ( 8A ) Pidato Bahasa Indonesia
  4. Hafizhan Arhab Juswil ( 8F ) Pidato Bahasa Arab
  5. Kevin Prasetyo ( 8C ) Pidato Bahasa Inggris
  6. Luqman Hakim ( 8F ) Pidato Bahasa Inggris
  7. Muhammad Attariq Hafidz ( 8F ) Musabaqah Hifdzil Qur'an
  8. Muhammad Syauqi Dhiya'ul Haq ( 8C ) Pidato Bahasa Indonesia
  9. Yanayyir Rifai ( 8E ) Pidato Bahasa Arab
  10. Yusuf Ramadhan ( 8A ) Musabaqah Tilawatil Qur'an

Nah, Alhamdulillah siswa-siswa Mu'allimin bimbingan kak Ilham Fanani ( 11 IPA 2 ), kak Muhammad Ulil Albab ( 11 MAK 2 ) dan Rizky Fathan Azkia ( 10 MAK ) ini dapat mempersembahkan kepada para juri, performa terbaik mereka semua.



Dan alhamdulillah, 3 diantaranya dapat membawa pulang piala bagi madrasah.

Arif Rachman Mustafa: Juara 3 Pidato Bahasa Indonesia

Yusuf Ramadhan: Juara 3 Musabaqah Tilawatil Qur'an

Hafizhan Arhab Juswil: Juara harapan 1 Pidato Bahasa Arab



It’s enough to be proud to all of you.

7

Nadie puede imaginar como comienza…
Algún día la vi y me pareció bonita, de cierto modo
me identifique con ella.
Un día me entere que estaría conviviendo con ella
al menos 2 años.
Nuestros gustos e ideas eran similares, por lo que nos hicimos
compañeras.
La miraba 8 horas, 5 veces  a la semana.
Tal vez ahí.. empezó nuestra historia.
16 años, pretendíamos comernos el mundo.
Respetaba mis ideas, como yo las suyas.
Siempre fue mas madura y desde el inicio,
su hombro siempre estuvo disponible para
una niña inmadura y sensible.
Ella decía lo que mis oídos querían escuchar,
sus palabras eran plena sabiduría.
Escucho las buenas y las malas noticias,
mis mejores y los peores días estuvo conmigo.
No recuerdo cuando fue la primera vez
que le llame “mejor amiga” , en realidad no
importa tanto recordarlo, ambas tenemos
recuerdos de la adolescencia que guardamos
en la memoria.
BEST F R I E N D S NEVER END

July 29, 2015 Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development

July 29, 2015 Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development


July 29, 2015

Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development

Quebec City, Canada, July 29, 2015 - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced it has selected an optimized Erk inhibitor molecule for development, thus achieving another important milestone in the development of a new class of potential cancer therapies.

The MAPK pathway represents a prime target for therapeutic intervention in cancer. Recently approved compounds demonstrate significant antitumor activities and survival benefits for B-Raf and Mek inhibitors. Erk inhibitors may be preferred agents in tumors with aberrant MAPK pathway activity, e.g. in tumors with mutated or wildtype B-Raf, mutated or wildtype ras, and in tumors with acquired resistance to Raf and Mek inhibitors.

At the 2014 American Association for Cancer Research’s annual meeting, the Company presented an abstract of its work on an Erk inhibitor molecule called “AEZS-134”. The abstract was selected by participants in the meeting as one of the 11 high-impact abstracts out of hundreds presented on the topic. Subsequently to this recognition, the Company continued its efforts on the Erk inhibitor program, including identification of an optimized molecule.

An optimized Erk inhibitor compound, AEZS-140, and back-up candidates were identified as a result of the development efforts. AEZS-140 and the back-up candidates demonstrate improved plasma exposure in rodents as well as enhanced anti-tumor efficacy in comparison to the previous lead compound, AEZS-134. Furthermore, AEZS-140 was profiled against several clinical Raf, Mek and Erk inhibitors and demonstrated very competitive activity.

The Company will proceed with the next development steps for AEZS-140 and the back-up compounds, including in depth profiling in vitro and, also, further in vivo tumor models. The Company is seeking proposals from parties who are interested in either co-developing or licensing the compounds.

David A. Dodd, Chairman and CEO of Aeterna Zentaris, commented, “Our strategy includes leveraging some of our promising early-stage drug candidates in order to generate potential long-term value without having to invest in their development. We are pursuing this strategy with respect to our Erk inhibitor development program. A therapeutic agent arising from this program could represent a novel approach to treating types of cancers with acquired resistance to Raf and Mek inhibitors. Our business development team is already engaged in discussions with parties who have previously expressed an interest in our work with Erk inhibitors.”

About Aeterna Zentaris

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. For more information, visit www.aezsinc.com .

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of the Company to efficiently commercialize one or more of its products or product candidates, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process, the ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.

Contact

Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406
pburroughs@aezsinc.com

-30-

Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development

QUEBEC CITY , July 29, 2015 /CNW Telbec/ - Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) (the "Company") today announced it has selected an optimized Erk inhibitor molecule for development, thus achieving another important milestone in the development of a new class of potential cancer therapies.

The MAPK pathway represents a prime target for therapeutic intervention in cancer. Recently approved compounds demonstrate significant antitumor activities and survival benefits for B-Raf and Mek inhibitors. Erk inhibitors may be preferred agents in tumors with aberrant MAPK pathway activity, e.g. in tumors with mutated or wildtype B-Raf, mutated or wildtype ras, and in tumors with acquired resistance to Raf and Mek inhibitors.

At the 2014 American Association for Cancer Research’s annual meeting, the Company presented an abstract of its work on an Erk inhibitor molecule called “AEZS-134”. The abstract was selected by participants in the meeting as one of the 11 high-impact abstracts out of hundreds presented on the topic. Subsequently to this recognition, the Company continued its efforts on the Erk inhibitor program, including identification of an optimized molecule.

An optimized Erk inhibitor compound, AEZS-140, and back-up candidates were identified as a result of the development efforts. AEZS-140 and the back-up candidates demonstrate improved plasma exposure in rodents as well as enhanced anti-tumor efficacy in comparison to the previous lead compound, AEZS-134. Furthermore, AEZS-140 was profiled against several clinical Raf, Mek and Erk inhibitors and demonstrated very competitive activity.  

The Company will proceed with the next development steps for AEZS-140 and the back-up compounds, including in depth profiling in vitro and, also, further in vivo tumor models. The Company is seeking proposals from parties who are interested in either co-developing or licensing the compounds.

David A. Dodd , Chairman and CEO of Aeterna Zentaris, commented, “Our strategy includes leveraging some of our promising early-stage drug candidates in order to generate potential long-term value without having to invest in their development. We are pursuing this strategy with respect to our Erk inhibitor development program. A therapeutic agent arising from this program could represent a novel approach to treating types of cancers with acquired resistance to Raf and Mek inhibitors. Our business development team is already engaged in discussions with parties who have previously expressed an interest in our work with Erk inhibitors.”

About Aeterna Zentaris

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. For more information, visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of the Company to efficiently commercialize one or more of its products or product candidates, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process, the ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements.  Investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.

SOURCE Aeterna Zentaris Inc.

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; }
Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development

QUEBEC CITY, July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) (the "Company") today announced it has selected an optimized Erk inhibitor molecule for development, thus achieving another important milestone in the development of a new class of potential cancer therapies.

The MAPK pathway represents a prime target for therapeutic intervention in cancer. Recently approved compounds demonstrate significant antitumor activities and survival benefits for B-Raf and Mek inhibitors. Erk inhibitors may be preferred agents in tumors with aberrant MAPK pathway activity, e.g. in tumors with mutated or wildtype B-Raf, mutated or wildtype ras, and in tumors with acquired resistance to Raf and Mek inhibitors.

At the 2014 American Association for Cancer Research’s annual meeting, the Company presented an abstract of its work on an Erk inhibitor molecule called “AEZS-134”. The abstract was selected by participants in the meeting as one of the 11 high-impact abstracts out of hundreds presented on the topic. Subsequently to this recognition, the Company continued its efforts on the Erk inhibitor program, including identification of an optimized molecule.

An optimized Erk inhibitor compound, AEZS-140, and back-up candidates were identified as a result of the development efforts. AEZS-140 and the back-up candidates demonstrate improved plasma exposure in rodents as well as enhanced anti-tumor efficacy in comparison to the previous lead compound, AEZS-134. Furthermore, AEZS-140 was profiled against several clinical Raf, Mek and Erk inhibitors and demonstrated very competitive activity.  

The Company will proceed with the next development steps for AEZS-140 and the back-up compounds, including in depth profiling in vitro and, also, further in vivo tumor models. The Company is seeking proposals from parties who are interested in either co-developing or licensing the compounds.

David A. Dodd, Chairman and CEO of Aeterna Zentaris, commented, “Our strategy includes leveraging some of our promising early-stage drug candidates in order to generate potential long-term value without having to invest in their development. We are pursuing this strategy with respect to our Erk inhibitor development program. A therapeutic agent arising from this program could represent a novel approach to treating types of cancers with acquired resistance to Raf and Mek inhibitors. Our business development team is already engaged in discussions with parties who have previously expressed an interest in our work with Erk inhibitors.”

About Aeterna Zentaris

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. For more information, visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of the Company to efficiently commercialize one or more of its products or product candidates, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process, the ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements.  Investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.

span.p_span{font-size:8pt !important;font-family:"Arial" !important;color:black !important;} a.p_a{color:blue !important;} li.p_li{font-size:8pt !important;font-family:"Arial" !important;color:black !important;} p.p_p{font-size:0.62em !important;font-family:"Arial" !important;color:black !important;margin:0in !important;} ;} p.c1 {font-weight: bold !important;} ;}
Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; }

QUEBEC CITY, July 29, 2015 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:AEZS - News) (TSX: AEZ) (the "Company") today announced it has selected an optimized Erk inhibitor molecule for development, thus achieving another important milestone in the development of a new class of potential cancer therapies.

The MAPK pathway represents a prime target for therapeutic intervention in cancer. Recently approved compounds demonstrate significant antitumor activities and survival benefits for B-Raf and Mek inhibitors. Erk inhibitors may be preferred agents in tumors with aberrant MAPK pathway activity, e.g. in tumors with mutated or wildtype B-Raf, mutated or wildtype ras, and in tumors with acquired resistance to Raf and Mek inhibitors.

At the 2014 American Association for Cancer Research’s annual meeting, the Company presented an abstract of its work on an Erk inhibitor molecule called “AEZS-134”. The abstract was selected by participants in the meeting as one of the 11 high-impact abstracts out of hundreds presented on the topic. Subsequently to this recognition, the Company continued its efforts on the Erk inhibitor program, including identification of an optimized molecule.

An optimized Erk inhibitor compound, AEZS-140, and back-up candidates were identified as a result of the development efforts. AEZS-140 and the back-up candidates demonstrate improved plasma exposure in rodents as well as enhanced anti-tumor efficacy in comparison to the previous lead compound, AEZS-134. Furthermore, AEZS-140 was profiled against several clinical Raf, Mek and Erk inhibitors and demonstrated very competitive activity.  

The Company will proceed with the next development steps for AEZS-140 and the back-up compounds, including in depth profiling in vitro and, also, further in vivo tumor models. The Company is seeking proposals from parties who are interested in either co-developing or licensing the compounds.

David A. Dodd, Chairman and CEO of Aeterna Zentaris, commented, “Our strategy includes leveraging some of our promising early-stage drug candidates in order to generate potential long-term value without having to invest in their development. We are pursuing this strategy with respect to our Erk inhibitor development program. A therapeutic agent arising from this program could represent a novel approach to treating types of cancers with acquired resistance to Raf and Mek inhibitors. Our business development team is already engaged in discussions with parties who have previously expressed an interest in our work with Erk inhibitors.”

About Aeterna Zentaris

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. For more information, visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of the Company to efficiently commercialize one or more of its products or product candidates, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process, the ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements.  Investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.

SOURCE Aeterna Zentaris Inc.

Watch on oncologytube.tumblr.com

Targeting the MAPK Pathway in GI Malignancies

TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2015

NEW YORK, July 20, 2015 /PRNewswire/ – The TNF-alfa signaling pathway stimulates the MAPK signaling module and activates NFkB.
There are today 482 companies plus partners developing 642 TNF-alpha pathway targeting drugs in 2523 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 299 drugs. Tnf-Alpha Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 280 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 275 out of the 276 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 59 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?
* Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.

Drug Pipeline Update at a Glance

Investigators
Includes more than 482 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.

Drug name & Synonyms
Lists commercial, generic and code names for drugs.

Developmental stage
This Drug Pipeline Update contains 642 TNF-alpha pathway targeting drugs in development, which have a total of 2523 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs
Marketed# 46
Registered# 1
Pre-registration# 4
Phase III# 70
Phase II# 213
Phase I# 258
Preclinical# 455
No Data# 23
Suspended# 6
Ceased# 299

Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.

Indications
Included TNF-alpha pathway targeting drugs are also in development for 260 other indications, where of 168 are different cancer indications.

Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.

Targets
Mutations
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 275 out of the 276 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.

Biological Structures
The identity of available biological structures on 236 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 4794 structures available today among drug targets.

Identified drugs are linked to more than 280 different targets, divided into 59 classifications of molecular function:
- Acid phosphatase activity
- ATPase activity
- Binding
- Carboxypeptidase activity
- Caspase activator activity
- Catalytic activity
- Cell adhesion molecule activity
- Chaperone activity
- Chromatin binding
- Cysteine-type peptidase activity
- Cytokine activity
-
- Deacetylase activity
- DNA binding
- DNA repair protein
- DNA topoisomerase activity
- Extracellular matrix structural constituent
- G-protein coupled receptor activity
- Glutathione transferase activity
- Growth factor activity
- GTPase activity
- Heat shock protein activity
- Isomerase activity
- Kinase activity
- Kinase binding
- Kinase regulator activity
- Ligand-dependent nuclear receptor activity
- Ligase activity
- Lipid kinase activity
- Lipid phosphatase activity
- Metallopeptidase activity
- Molecular function unknown
- Oxidoreductase activity
- Peroxidase activity
- Protease inhibitor activity
- Protein binding
- Protein serine/threonine kinase activity
- Protein threonine/tyrosine kinase activity
- Protein tyrosine phosphatase activity
- Protein tyrosine/serine/threonine phosphatase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor binding
- Receptor signaling complex scaffold activity
- Receptor signaling protein serine/threonine kinase activity
- Serine-type peptidase activity
- Signal transducer activity
- Structural constituent of cytoskeleton
- Structural molecule activity
- Superoxide dismutase activity
- T cell receptor activity
- T cell receptor binding
- Transcription factor activity
- Transcription regulator activity
- Translation regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity
- Transporter activity
- Ubiquitin-specific protease activity
- Unclassified

Sub-Cellular Localization
Identified targets are categorized into 38 different primary and alternate sub-cellular localizations:
- Basolateral membrane
- Cell junction
- Cell projection
- Centrosome
- Chromosome
- Clathrin-coated vesicle
- Cytoplasm
- Cytoplasmic vesicle
- Cytoskeleton
- Cytosol
- Endoplasmic reticulum
- Endosome
- Extracellular
- Extracellular matrix
- Focal adhesion
- Golgi apparatus
- Golgi membrane
- Immunological synapse
- Integral to membrane
- Kinetochore
- Lysosome
- Membrane fraction
- Microtubule
- Mitochondrial membrane
- Mitochondrion
- Nuclear membrane
- Nucleolus
- Nucleoplasm
- Nucleus
- Perinuclear region
- Perinuclear vesicle
- Peroxisome
- Plasma membrane
- Ribosome
- Sarcoplasmic reticulum
- Secreted
- Synaptic vesicle
- Vesicle

Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.

Target Expression Profile
Direct links are provided from inside the application to 435 protein expression profiles of 258 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells

Pathway Referals
Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.
- BioCarta# 252 Pathways
- KEGG# 175 Pathways
- NCI-Nature# 254 Pathways
- NetPath# 32 Pathways

Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.

Mechanism
In total there are different drug mechanism of action represented in this Drug Pipeline Update.

Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.

Compound
Identified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.

Drug Profile
Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:

Drug Name & Synonyms
Presentation of drug name and synonyms

Principal Company & Partners
Presentation of principal company and partners

Target and Molecular Function of Target
Described target(s) is/are presented with:
Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function

Target Localization
Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells

Mutation
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.

Biological Structures
The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.

Targeted Pathways
Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.

Mechanism
Drug mechanism of action

Developmental Projects
Summary field of developmental projects for the drug, including indication, developmental stage and status.
Example:
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased

Drug Description
Short introduction to drug

Compound Data
Compound type, Chemical name, CAS Number and molecular weight

Patent Data
Available patent information related to the drug is presented here.

Fillings and Approvals
Approvals and submissions
Analyst comments

Deals & Licensing
Collaborations and deals
Availability for licensing

Phase IV Data
Available Phase IV development data, developmental history and scientific data.

Phase III Data
Available Phase III development data, developmental history and scientific data.

Phase II Data
Available Phase II development data, developmental history and scientific data.

Phase I Data
Available Phase I development data, developmental history and scientific data.

Phase 0 Data
Available Phase 0 development data, developmental history and scientific data.

Preclinical Data
Available preclinical development data, developmental history and scientific data.

Discovery Data
Available discovery development data, developmental history and scientific data.

Application Features
Search, Find and Filter Panel with Initial Result Presentation
With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.


The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.

Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
- Direct links to company web pages of companies

Dynamic Report Generator
Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.




System Requirements
- Operating system: Windows (2000/XP/Vista/7/8) for Mac Users the service is only available online
- Browser Application (Internet Explorer, Firefox, Chrome, Safari)
- Internet access (to access related internet resources)
Read the full report: http://www.reportlinker.com/p0379915-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tnf-alpha-signaling-pathway-in-oncology-drug-pipeline-update-2015-300114897.html

span.p_span{font-size:8pt !important;font-family:"Arial" !important;color:black !important;} a.p_a{color:blue !important;} li.p_li{font-size:8pt !important;font-family:"Arial" !important;color:black !important;} p.p_p{font-size:0.62em !important;font-family:"Arial" !important;color:black !important;margin:0in !important;} ;}